Status:
COMPLETED
Biologic Correlative Taxotere/AC
Lead Sponsor:
Baylor Breast Care Center
Collaborating Sponsors:
Baylor College of Medicine
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
We are asking you to take part in a research study of biomarkers (characteristics or traits of the genes inside cancer cells). We want to learn if these biomarkers could help us learn how well your br...
Detailed Description
Breast cancer and systemic chemotherapy: Systemic chemotherapy for operable breast cancer significantly decreases the risk of relapse and death. However, it is not possible to identify those patients ...
Eligibility Criteria
Inclusion
- All patients must be female.
- Signed informed consent.
- Primary breast cancers must be of clinical and/or radiologic size \>3 cm, and deemed surgically operable.
- Negative serum pregnancy test (bHCG) within 7 days of starting study, if of child-bearing potential.
- Adequate bone marrow function: Hematocrit of greater than 30%, total neutrophil count must be \>1.5 x 109/L and platelets of \> 100 x 109/L prior to the start of any cycle.
- Renal function tests: creatinine within 1.5 times of the institution's upper limit of normal (ULN).
- Liver function tests: Total serum bilirubin within ULN, and liver transaminases within 2.5 times ULN, and alkaline phosphatase within 5 times ULN.
- Electrocardiogram showing no acute ischemic changes.
- Performance status (WHO scale) \<2.
- Age \> 18 years.
- Patients older than 70 years of age should have left ventricular ejection fraction within ULN by MUGA or 2D Echocardiogram.
Exclusion
- Patients with metastatic breast cancer.
- Pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential.
- Women who are lactating or breastfeeding.
- Severe underlying chronic illness or disease.
- Peripheral neuropathy - grade 2 or greater.
- Patients on other investigational drugs while on study will be excluded.
- Severe or uncontrolled hypertension, history of congestive heart failure, acute myocardial infarction, or severe coronary arterial disease.
- Prior taxane or anthracycline chemotherapy for malignancy.
- Patients with a history of severe hypersensitivity reaction to Taxotere or other drugs formulated with polysorbate 80.
- No previous or current malignancies at other sites within the last 5 years, with exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.
Key Trial Info
Start Date :
April 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00206466
Start Date
April 1 2002
End Date
January 1 2012
Last Update
January 25 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baylor Breast Center
Houston, Texas, United States, 77030